Acceleration of the world’s first autotaxin inhibitor for the treatment of pancreatic cancer (PDAC)

Fact Sheet

Project Information

CURE-PDAC

Grant agreement ID: 190159801

Funded under
The European Innovation Council (EIC)

DOI
10.3030/190159801

Total cost
€ 5 906 503,00

EU contribution
€ 2 500 000,00

Start date
1 October 2022

End date
31 March 2025

Coordinated by
IONCTURA BV
Netherlands

Objective

iOnctura is a clinical stage biopharmaceutical company dedicated to delivering innovative cancer treatments to patients with unmet medical needs. iOnctura’s unique pipeline of drugs unlock mechanisms at the tumour-stroma-immune (T-S-I) interface, a multi cell-network that is responsible for driving tumour growth and survival as well as treatment resistance.

Pancreatic cancer is one of the most lethal cancers associated with devastating impact on the quality of life of patients; current treatments are largely ineffective and there is a need for game-changing therapies. IOA-289, is a first in class autotaxin (ATX) inhibitor that tackles cancer growth and spread by affecting core mechanisms at the T-S-I interface.
The EIC Accelerator funding for CURE-PDAC will allow iOnctura to accelerate the clinical development of IOA-289 as a treatment for pancreatic cancer through Phase I/II clinical trials, reach a major value inflection point and attract further financial investment into the company.

**Fields of science**

[medical and health sciences]  [clinical medicine]  [oncology]  [pancreatic cancer]

**Keywords**

Health  Oncology  Drugs  pancreatic cancer  immunotherapy  fibrotic disease  clinical development  pharmaceutical industry

**Programme(s)**

HORIZON.3.1 - The European Innovation Council (EIC)  MAIN PROGRAMME

**Topic(s)**

HORIZON-EIC-2022-ACCELERATOROPEN-01 - EIC Accelerator Open

**Call for proposal**

HORIZON-EIC-2022-ACCELERATOR-01

See other projects for this call

**Funding Scheme**

HORIZON-EIC-ACC-BF - HORIZON EIC Accelerator Blended Finance

**Coordinator**
IONCTURA BV

Net EU contribution
€ 2,500,000,00

Address
Gustav mahlerplein 102
1082 MA Amsterdam
Netherlands

Region
West-Nederland > Noord-Holland > Groot-Amsterdam

Activity type
Private for-profit entities (excluding Higher or Secondary Education Establishments)

Links
Contact the organisation
Participation in EU R&I programmes
HORIZON collaboration network

Other funding
€ 3,406,503,00

EC signature date 6 April 2023
Last update: 25 July 2023

Permalink: https://cordis.europa.eu/project/id/190159801

European Union, 2023